Extremely prolonged neuromuscular blockade following a single dose of rocuronium in a dog

[1]  Yong Beom Kim,et al.  Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents , 2017, Korean journal of anesthesiology.

[2]  Soon-Hyun Ahn,et al.  Magnesium sulfate accelerates the onset of low-dose rocuronium in patients undergoing laryngeal microsurgery. , 2017, Journal of clinical anesthesia.

[3]  Fadhil Zwer.  Factors Affect Neuromuscular Transmission and Block , 2016 .

[4]  T. Nishiyama,et al.  The neuromuscular effects of rocuronium under sevoflurane-remifentanil or propofol-remifentanil anesthesia: a randomized clinical comparative study in an Asian population , 2015, BMC Anesthesiology.

[5]  M. Mosing,et al.  Reversal of neuromuscular block in companion animals. , 2015, Veterinary anaesthesia and analgesia.

[6]  S. Lobaz,et al.  Sugammadex rescue following prolonged rocuronium neuromuscular blockade with ‘recurarisation’ in a patient with severe renal failure , 2013, BMJ Case Reports.

[7]  P. Dobbs.  Drugs in Anaesthesia and Intensive Care , 2011 .

[8]  A. Stegeman,et al.  Extremely prolonged neuromuscular block after cardiopulmonary resuscitation , 2011 .

[9]  A. C. Morales Martín,et al.  Extremely prolonged neuromuscular blockade after rocuronium: a case report , 2009, Acta anaesthesiologica Scandinavica.

[10]  J. Hunter,et al.  Reversal of neuromuscular block. , 2009, British journal of anaesthesia.

[11]  J. Viby-Mogensen,et al.  Prolonged residual paralysis after a single intubating dose of rocuronium. , 2007, British journal of anaesthesia.

[12]  A. Dugdale,et al.  Use of rocuronium administered by continuous infusion in dogs. , 2007, Veterinary anaesthesia and analgesia.

[13]  A. Bom,et al.  Selective relaxant binding agents for reversal of neuromuscular blockade. , 2007, Current opinion in pharmacology.

[14]  B. Meibohm,et al.  The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy , 2007, International Journal of Impotence Research.

[15]  U. Auer.  Clinical observations on the use of the muscle relaxant rocuronium bromide in the dog. , 2007, Veterinary journal.

[16]  J. van Egmond,et al.  Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. , 2006, British journal of anaesthesia.

[17]  Jennifer M Hunter,et al.  Monitoring of neuromuscular block , 2006 .

[18]  W. Bowman.  Neuromuscular block , 2006, British journal of pharmacology.

[19]  I. A. Gomez de Segura,et al.  Neuromuscular blocking properties of atracurium during sevoflurane or propofol anaesthesia in dogs. , 2005, Veterinary anaesthesia and analgesia.

[20]  N. Unwin,et al.  Refined structure of the nicotinic acetylcholine receptor at 4A resolution. , 2005, Journal of molecular biology.

[21]  J. Driessen,et al.  Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure , 2005, European journal of anaesthesiology.

[22]  M. Giala,et al.  Rocuronium duration of action under sevoflurane, desflurane or propofol anaesthesia , 2004, European journal of anaesthesiology.

[23]  J. Hunter,et al.  Anticholinesterases and anticholinergic drugs , 2004 .

[24]  A. Dugdale,et al.  The clinical use of the neuromuscular blocking agent rocuronium in dogs. , 2002, Veterinary anaesthesia and analgesia.

[25]  E. Martin,et al.  Rocuronium potency and recovery characteristics during steady-state desflurane, sevoflurane, isoflurane or propofol anaesthesia. , 2000, British journal of anaesthesia.

[26]  D. Bevan,et al.  Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children. , 1999, Anesthesia and analgesia.

[27]  R. Mirakhur,et al.  Neuromuscular Effects of Rocuronium During Sevoflurane, Isoflurane, and Intravenous Anesthesia , 1998, Anesthesia and analgesia.

[28]  P. Lindholm,et al.  Time to peak effect of neostigmine at antagonism of atracurium- or vecuronium-induced neuromuscular block. , 1995, Journal of clinical anesthesia.

[29]  J. Wierda,et al.  Clinical pharmacology of rocuronium (Org 9426): study of the time course of action, dose requirement, reversibility, and pharmacokinetics. , 1994, Journal of clinical anesthesia.

[30]  A. Muir,et al.  Interaction between rocuronium bromide and some drugs used during anaesthesia. , 1994, European journal of anaesthesiology. Supplement.

[31]  R. Marshall,et al.  An overview of the pharmacology of rocuronium bromide in experimental animals. , 1994, European journal of anaesthesiology. Supplement.

[32]  C. Lien,et al.  Depression of neuromuscular function in a patient during desflurane anesthesia. , 1993, Anesthesia and analgesia.

[33]  J. Changeux,et al.  The acetylcholine receptor: functional architecture and regulation. , 1990, Advances in second messenger and phosphoprotein research.

[34]  P. Duvaldestin,et al.  Binding of tubocurarine, fazadinium, pancuronium and Org NC 45 to serum proteins in normal man and in patients with cirrhosis. , 1982, British journal of anaesthesia.

[35]  M. Ghoneim,et al.  Binding of d‐Tubocurarine to Plasina Proteins in Normal Man and in Patients with Hepatic or Renal Disease , 1973, Anesthesiology.

[36]  H. H. Ali,et al.  QUANTITATIVE ASSESSMENT OF RESIDUAL ANTIDEPOLARIZING BLOCK (PART II) , 1971 .

[37]  B. Katz,et al.  The effect of calcium on acetylcholine release from motor nerve terminals , 1965, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[38]  D. Pickett.  Curare in canine surgery. , 1951, Journal of the American Veterinary Medical Association.

[39]  Johnson,et al.  THE USE OF CURARE IN GENERAL ANESTHESIA , 1942 .